Rare disease drug developer Ultragenyx Pharmaceutical (NASDAQ: [[ticker:RARE]]) has named Camille Bedrosian executive vice president and chief medical officer. Before joining the Novato, CA-based company, Bedrosian was senior vice president and chief medical officer of Alexion Pharmaceuticals (NASDAQ: [[ticker:ALXN]]) in New Haven, CT. Ultragenyx added gene therapy to its drug pipeline last fall through its acquisition of Cambridge, MA-based Dimension Therapeutics.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
